Phase 2a clinical trial assessing INVA8001
Latest Information Update: 17 Dec 2024
Price :
$35 *
At a glance
- Drugs INVA 8001 (Primary)
- Indications Chronic urticaria
- Focus Adverse reactions; Therapeutic Use
- 17 Dec 2024 New trial record
Latest Information Update: 17 Dec 2024